Work

Real-world outcomes of olaparib with versus without bevacizumab in bevacizumab-naïve BRCA1/2-mutated ovarian cancer.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5574

Authors: Love Kumar, Jennifer Collins, Courtney Nail, Amir Kamran, Stephen Bush

Institution: Charleston Area Medical Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162513680

Cites:

Cited by:

Related to: